Dan Chambers

Professor Chambers is a recognised thought leader in the fields of lung fibrosis, lung cell therapy and lung transplantation. His contributions to these fields have translated into improvements in the management of a wide range of serious lung diseases including silicosis, lung transplant rejection, lung fibrosis and grown up neonatal lung disease. Dan pioneered the use of whole lung lavage to treat acute silicosis, work that has been featured in international media. He was a key member of the team which pioneered ex-vivo lung perfusion to resuscitate marginal donor organs in Australia in 2011. He has used this technology to improve the safety of early phase human trials, and in so doing conceived and developed guidelines for the use of donated human lungs for research in Australia, a document now endorsed by the Transplantation Society of Australia and New Zealand and utilised around the country.

His contribution to knowledge in these diverse areas has been recognised in his appointment to several governmental panels including the Biologicals Advisory Committee (Therapeutic Goods Administration, 2017-2019), the Interim Advisory Panel of the Notifiable Dust Lung Disease Register (Qld Government, 2020-2021), the Virtual Cross Match Working Group (Organ and Tissue Authority, 2020-2021) and the Registry Build Advisory Group for the National Occupational Lung Disease Registry (Australian Government Department of Health, 2020-). He has either chaired or contributed to committees and working groups which have developed international position statements or guidelines in diverse areas of advanced lung disease including the management of fungal infection, conduct of bronchoalveolar lavage, donor and recipient lung transplant management, and in the diagnosis and management of interstitial lung disease. He runs one of the world's largest clinical trial centres focussed on interstitial lung disease and has collaborated with multiple academic and industry partners to bring new treatments to patients with serious lung disease. His work is regularly featured in the Australian media.